Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

How PSMA expression is differentially regulated across metastatic lesions and in the context of the AR may inform selection for PSMA-targeted therapies and development of complementary biomarkers is demonstrated.